Evaluation of pre‐analytic heat treatment protocol used in the CDC Nijmegen‐Bethesda assay for heat inactivation of extended half‐life haemophilia treatment products-Reference-Cited by-同舟云学术

Evaluation of pre‐analytic heat treatment protocol used in the CDC Nijmegen‐Bethesda assay for heat inactivation of extended half‐life haemophilia treatment products

Published:2019-12-06 Issue:1 Volume:26 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Payne Amanda B.¹^ORCID,Ellingsen Dorothy¹,Driggers Jennifer¹,Bean Christopher J.¹^ORCID,Miller Connie H.¹

Affiliation:

1. National Center on Birth Defects and Developmental Disabilities Division of Blood Disorders Centers for Disease Control and Prevention Atlanta GA USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13901

Reference4 articles.

1. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels

2. Extended Half-Life Factor VIII and Factor IX Preparations

3. Heat inactivation of extended half‐life factor VIII concentrates

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional determination of emicizumab in presence of factor VIII activity;Journal of Thrombosis and Haemostasis;2023-12

2. International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors;International Journal of Laboratory Hematology;2023-06-07

3. Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels;PLOS ONE;2022-07-14

4. An Update on Laboratory Diagnostics in Haemophilia A and B;Hämostaseologie;2022-02-01

5. Evaluation of anti‐factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents;Haemophilia;2020-11-20